BACKGROUND AND PURPOSE: This study presents a statistical model to explore the presence of a population-based cure fraction in populations with a GBM. PATIENTS AND METHODS: Data for this study was obtained from the Surveillance, Epidemiology and End-Results (SEER) database. Relative survival measures were modelled using non-mixture cure fraction models. RESULTS: The extraction and subsequent period modeling of the dataset resulted in a final total of 11,189 patients and a total of 10,289 years of patient follow-up (between 2001 and 2006). The cure fraction of young adults is expected to be 12% (95% CI 7-16), which is estimated to occur at a minimum time of 10 years post diagnosis. INTERPRETATION: The data, using population-based cure fraction models, indicate that a possibility for cure appears to be present in the young adult population, and occurs at 10 years after diagnosis. Because of the biological and statistical features of this patient population, it is appropriate to study GBM populations using cure fraction models.
BACKGROUND AND PURPOSE: This study presents a statistical model to explore the presence of a population-based cure fraction in populations with a GBM. PATIENTS AND METHODS: Data for this study was obtained from the Surveillance, Epidemiology and End-Results (SEER) database. Relative survival measures were modelled using non-mixture cure fraction models. RESULTS: The extraction and subsequent period modeling of the dataset resulted in a final total of 11,189 patients and a total of 10,289 years of patient follow-up (between 2001 and 2006). The cure fraction of young adults is expected to be 12% (95% CI 7-16), which is estimated to occur at a minimum time of 10 years post diagnosis. INTERPRETATION: The data, using population-based cure fraction models, indicate that a possibility for cure appears to be present in the young adult population, and occurs at 10 years after diagnosis. Because of the biological and statistical features of this patient population, it is appropriate to study GBM populations using cure fraction models.
Authors: Elisa Mazzoni; Massimo Gerosa; Francesco Lupidi; Alfredo Corallini; Angelo Pio Taronna; Antonio D'Agostino; Massimo Bovenzi; Giuseppina Ruggeri; Ferruccio Casali; John Charles Rotondo; Giovanni Rezza; Giuseppe Barbanti-Brodano; Mauro Tognon; Fernanda Martini Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: Alexandra Rizzitelli; Nicolas R Smoll; Michael P Chae; Warren M Rozen; David J Hunter-Smith Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: Bawarjan Schatlo; Javier Fandino; Nicolas R Smoll; Oliver Wetzel; Luca Remonda; Serge Marbacher; Wolfgang Perrig; Hans Landolt; Ali-Reza Fathi Journal: Neuro Oncol Date: 2015-04-08 Impact factor: 12.300
Authors: Jamison Beiriger; Ahmed Habib; Nicolina Jovanovich; Chowdari V Kodavali; Lincoln Edwards; Nduka Amankulor; Pascal O Zinn Journal: Front Oncol Date: 2022-03-10 Impact factor: 6.244